#United States #New York #Gross Law Firm #Securities Class Action #Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. Under Fire: Legal Action from The Gross Law Firm

In a significant development for investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), The Gross Law Firm has filed a securities class action alert for shareholders who purchased stock during the specified class period. The firm encourages those affected to reach out regarding potential lead plaintiff appointments, although participation in the recovery process does not require such appointments.

Understanding the Case

The class action case arises from allegations that Ultragenyx made misleading representations about the efficacy of its lead product, setrusumab. Shareholders are specifically advised to register if they acquired shares between August 3, 2023, and December 26, 2025. It's crucial for these investors to understand that, while setrusumab was indicated to increase bone density, the actual studies revealed that this increase did not correspond to a reduced rate of fractures, which was a key claim made by the company’s management.

On December 29, 2025, Ultragenyx disclosed that both its Phase III studies—Orbit and Cosmic—failed to meet their primary endpoints concerning fracture reduction when compared to placebo or bisphosphonates. This announcement triggered a catastrophic drop in the company’s share price, which plummeted from $34.19 to $19.72 in a single day—marking a devastating reduction of about 42%.

Implications for Shareholders

The firm has set a deadline of April 6, 2026, for potential lead plaintiffs to come forward. Time is of the essence for shareholders, as the quicker they proceed, the better positioned they will be to claim their share of any potential recovery. Once registered, investors will gain access to a portfolio monitoring system that provides them with updates throughout the life of the case.

Why Choose The Gross Law Firm?

The Gross Law Firm is a recognized authority in the field of class actions, focusing on the rights of investors who have faced losses due to deceptive practices. The fundamental aim of the firm is to uphold corporate responsibility and good practices, particularly when misconduct impacts stock prices adversely. Investors can initiate their claims without needing to pay upfront legal fees, showcasing the firm's commitment to protecting shareholder interests.

Next Steps

Investors who believe they may be entitled to damages should not delay in registering their information via the firm's provided links. Participating in this class action represents a critical opportunity for affected shareholders to seek justice and potentially recover some of their losses incurred due to the alleged misinformation from Ultragenyx.

For those interested, further details can be found through contacting The Gross Law Firm directly at their office in New York or through their dedicated webpage for this case.

In conclusion, this legal action represents a crucial moment for shareholders of Ultragenyx Pharmaceutical Inc., and timely participation in the class action could pave the way for recovery in light of the recent troubling disclosures regarding company performance and transparency.